Objective:

To evaluate the efficacy and safety of gildeuretinol in reducing atrophic lesion growth in patients with Stargardt disease.

Key Findings:

• Gildeuretinol reduces toxic vitamin A dimerization by up to 80%.
• Well tolerated with mild to moderate treatment-emergent adverse events (TEAEs).
• No negative impact on the visual cycle observed.

Interpretation:

Gildeuretinol shows promise in slowing disease progression in Stargardt disease without adverse effects on visual function.

Limitations:

• TEASE-1's P value was not significant compared to TEASE-2.
• Interim analysis in TEASE-3 involved a small sample size.

Conclusion:

The TEASE program supports the potential of gildeuretinol as a treatment for Stargardt disease, with ongoing studies expected to provide further insights.